CMXC - Cell MedX Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
1.6200
+0.1300 (+8.72%)
As of 1:17PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.4900
Open1.4700
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.4700 - 1.6900
52 Week Range0.0500 - 1.6900
Volume255,265
Avg. Volume87,117
Market Cap78.299M
Beta (3Y Monthly)-0.49
PE Ratio (TTM)N/A
EPS (TTM)-0.0200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Newsfile

    Cell MedX Corp. Provides Corporate Update

    Carson City, Nevada--(Newsfile Corp. - September 12, 2019) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to provide its shareholders with a corporate update. Certifications In Fiscal year 2019 the Company received a Certificate of Conformity, from LabTest Certification Inc., for the ebalance Pro device (the "Device"). The certification ...

  • Newsfile

    Cell MedX Corp. Issues Clarifying Release Regarding the Bull Report Article

    Carson City, Nevada--(Newsfile Corp. - September 10, 2019) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focused on the discovery, development and commercialization of therapeutic and nontherapeutic products that promote general wellness, is issuing this news release to clarify that the article dated July 24, 2019 appearing in the TheBullReport.com was prepared on behalf of the Company.As previously announced, the Company has engaged the services of Think Ink ...

  • Newsfile

    CellMedX Corp. Receives Approval to Commence Family Practice (BC) Observational Study

    Carson City, Nevada--(Newsfile Corp. - August 19, 2019) - Cell MedX Corp. (OTCQB: CMXC) (MUN: 9CX) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the Company has received approval from the Board of Directors to commence a Family Practice (BC) - Observational Study of its ebalance device (the "Observational Trial", or the "Study"). ...

  • Newsfile

    Cell MedX Corp. (CMXC) Closes the First Tranche of its Non-Brokered Private Placement Financing

    Carson City, Nevada--(Newsfile Corp. - June 28, 2019) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), a bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that on June 24, 2019, the Company closed the first tranche of its non-brokered private placement offering (the "Offering") at a price of $0.12 per unit (the "Unit"), by issuing 3,950,000 Units ...

  • Newsfile

    Cell MedX Corp. Engages Think Ink Marketing

    Carson City, Nevada--(Newsfile Corp. - June 21, 2019) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that it has retained Think Ink Marketing Data & Email Services, Inc. ("Think Ink") to develop an investor outreach program. The Company agreed to pay Think Ink $25,000 for the first ...

  • Newsfile

    Cell MedX Corp. Arranges a Non-brokered Private Placement Financing

    Carson City, Nevada--(Newsfile Corp. - May 30, 2019) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, has arranged a non-brokered private placement offering (the "Offering") set at a price of $0.12 per Unit for up to 6,250,000 Units for total gross proceeds of $750,000. Each Unit sold under the Offering will consist ...

  • Newsfile

    Cell MedX Signs Definitive Worldwide Distribution Rights Agreement with Live Current Media, Inc.

    Carson City, Nevada--(Newsfile Corp. - March 27, 2019) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that on March 21, 2019, the Company entered into a definitive agreement for exclusive worldwide distribution rights of the ebalance device for home-use ("the "Agreement") with Live Current Media, Inc. ("LIVC"), ...

  • Newsfile

    Cell MedX Corp. Provides an Update on Progress Toward US Premarket Clearance and Clarifies its eBalance Certification

    Carson City, Nevada--(Newsfile Corp. - February 12, 2019) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness is pleased to announce significant progress toward obtaining premarket clearance in the US for its eBalance device. The eBalance device is not yet available for sale in the US.The Company has been ...

  • Newsfile

    Cell MedX Corp. Enters into Credit Line Agreement and Issues Warrants

    Carson City, Nevada--(Newsfile Corp. - December 31, 2018) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announces that on December 27, 2018, the Company entered into an Agreement with Mr. Richard Jeffs (the "Lender"), the Company's major shareholder (the "Agreement"), for an unsecured line of credit of up to ...

  • Newsfile

    Cell MedX Corp. Manufactures eBalance Devices in Canada

    Carson City, Nevada--(Newsfile Corp. - December 12, 2018) -  Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness is pleased to announce that it has successfully completed its first 100 Canadian manufactured eBalance devices.Upon receiving its Certificate of Conformity, qualifying the eBalance devices as Class A (professional use) and Class B ...

  • Newsfile

    Cell MedX Corp. Receives Safety and Electrical Certifications for the eBalance Pro Device

    Carson City, Nevada--(Newsfile Corp. - December 4, 2018) -  Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that the Company received electrical and safety certification for the Company's eBalance Pro device (the "Device"). The Company has received a Certificate of Conformity, from LabTest Certification Inc., ...